The Value of Serum α-Fetoprotein in Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma
Background Many patients with hepatocellular carcinoma (HCC) who undergo liver transplantation (LT) subsequently develop tumor recurrence; this is the main factor affecting long-term survival after LT. Factors associated with tumor recurrence should be determined to improve the outcome of LT. The purpose of the study was to evaluate the value of α-fetoprotein (AFP) in forecasting tumor recurrence after LT for patients with HCC. Methods AFP data before and after LT for 97 patients with HCC who underwent LT in our center were analyzed retrospectively. Results The mean follow-up time was 17.1 ± 2.1 months for all 97 patients, overall tumor recurrence rate was 32.9% (32/97), and mean recurrence time was 7.2 ± 3.2 months. The most common tumor recurrence sites were liver, lung, skeleton, and other sites. Pre-transplant AFP levels >400 ng/ml were associated with higher tumor recurrence. Post-transplant AFP levels not decreasing to ≤20 ng/ml within 2 months were also indicative of higher risk of recurrence. Conclusions Pre-transplant AFP and the dynamic change of AFP after LT were valuable in predicting tumor recurrence after LT for patients with HCC.
Keywordsα-Fetoprotein Recurrence Liver transplantation Hepatocellular carcinoma
This study was supported by a research grant from National Basic Research program of China (973 program, 2003CB515505) and the Fund for Science and Technology Department of Zhejiang Province (J20040701).
- 6.Figueras J, Ibanez L, Ramos E, Jaurrieta E, Ortiz-de-Urbina J, Pardo F, Mir J, Loinaz C, Herrera L, Lopez-Cillero P, Santoyo J (2001) Selection criteria for liver transplantation in early-stage hepatocellular carcinoma with cirrhosis: results of a multicenter study. Liver Transplant 7(10):877–883. doi: 10.1053/jlts.2001.27856 CrossRefGoogle Scholar
- 9.Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, Montalto F, Ammatuna M, Morabito A, Gennari L (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699. doi: 10.1056/NEJM199603143341104 PubMedCrossRefGoogle Scholar
- 10.Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S (2000) Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 88(3):538–543. doi:10.1002/(SICI)1097-0142(20000201)88:3<538::AID-CNCR7>3.0.CO;2-HGoogle Scholar
- 11.Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, Airoldi A, Giacomoni A, Rondinara G, Tinelli C, Forti D, Pinzello G (2005) Predictors of long-term survival after liver transplantation for hepatocellular carcinoma. Am J Gastroenterol 100(12):2708–2716. doi: 10.1111/j.1572-0241.2005.00289.x PubMedCrossRefGoogle Scholar
- 12.Pawlik TM, Delman KA, Vauthey JN, Nagorney DM, Ng IO, Ikai I, Yamaoka Y, Belghiti J, Lauwers GY, Poon RT, Abdalla EK (2005) Tumor size predicts vascular invasion and histologic grade: Implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 11(9):1086–1092. doi: 10.1002/lt.20472 PubMedCrossRefGoogle Scholar
- 14.Merli M, Nicolini G, Gentili F, Novelli G, Iappelli M, Casciaro G, Di Tondo U, Pecorella I, Marasco A, Onetti Muda A, Nudo F, Mennini G, Ginanni Corradini S, Riggio O, Berloco P, Attili AF, Rossi M (2005) Predictive factors of outcome after liver transplantation in patients with cirrhosis and hepatocellular carcinoma. Transplant Proc 37(6):2535–2540. doi: 10.1016/j.transproceed.2005.06.031 PubMedCrossRefGoogle Scholar